Oncology stocks

The best oncology stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

Our picks for the best oncology stocks

We round up a selection of stocks in or related to the cancer industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

---

1. Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

• Previous close price: $271.46
• Market capitalization: $139,459,379,200
• 1 year performance: 17.44%
• P/E ratio: 17.5569

Buy AMGN stock on Interactive Brokers

---

2. Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

• Previous close price: $58.78
• Market capitalization: $122,483,933,184
• 1 year performance: -17.81%
• P/E ratio: 15.5931

Buy BMY stock on Interactive Brokers

---

3. Five Prime Therapeutics (FPRX)

Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.

• Previous close price: $0.00
• Market capitalization: $1,769,735,936
• 1 year performance: N/A

Buy FPRX stock on Interactive Brokers

---

4. Gilead Sciences (GILD)

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

• Previous close price: $75.82
• Market capitalization: $96,391,331,840
• 1 year performance: 11.48%
• P/E ratio: 17.7839

Buy GILD stock on Interactive Brokers

---

5. Novartis AG ADR (NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians.

• Previous close price: $103.58
• Market capitalization: $210,610,913,280
• 1 year performance: 23.90%
• P/E ratio: 28.2861

Buy NVS stock on Interactive Brokers

---

6. Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

• Previous close price: $7.66
• Market capitalization: $82,652,824
• 1 year performance: -49.22%

Buy CRDF stock on Interactive Brokers

---

7. Surface Oncology (SURF)

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8.

• Previous close price: $7.12
• Market capitalization: $65,690,464
• 1 year performance: -23.57%

Buy SURF stock on Interactive Brokers

---

8. Trillium Therapeutics (TRIL)

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc.

• Previous close price: $8.63
• Market capitalization: $1,936,107,904
• 1 year performance: N/A

Buy TRIL stock on Interactive Brokers

---

9. Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.

• Previous close price: $1.27
• Market capitalization: $162,684,448
• 1 year performance: -84.11%

Buy MRSN stock on Interactive Brokers

Buy oncology stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

Bottom line

While it's possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you're new to investing, or if it's been awhile since you've taken a critical look at your investing accounts, compare brokers to make sure you're getting the best features in your trading account.